powered by
▸
healthparse
Search
Cohort Builder
Tools
▾
KOL Finder
Territories
Drug Compare
AI Query
Browse
▾
By state
By specialty
Pricing
Search
Cohort Builder
Tools
KOL Finder
Territories
Drug Compare
AI Query
Browse
By state
By specialty
Pricing
PROVIDER PROFILE · NPI 1043570930
Scott Sperling
M.D.
Endocrinology
Boston,
MA
I
CROSS-REFERENCE
Related data on other Healthparse brands
ProviderScore
OIG/SAM exclusion screening, sanctions history
QUALITY · MIPS · 2024
Final MIPS score
92.0
Quality
76.6
Cost
0.0
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.71%
APM Entity
PRESCRIBING · PART D · 2024
Total Rx claims
3,967
Beneficiaries
—
Total drug cost
$1.8M
Distinct drugs
39
Brand share
49.4%
Top prescribed drugs
Levothyroxine Sodium
504 claims
Dulaglutide
251 claims
Empagliflozin
242 claims
Metformin Hcl
203 claims
Semaglutide
199 claims
FACILITY AFFILIATIONS
Hospital & Facility Affiliations (5)
CCN 220029
Hospital
CCN 220033
Hospital
CCN 220086
Hospital
CCN 220105
Hospital
CCN 220171
Hospital
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
911
Unique beneficiaries
—
Total services
1,155
Distinct HCPCS
12
Medicare payment
$70K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 341 Endocrinology providers in MA — above median (cohort median 496).
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
No data available for this provider in 2024.
